Source facts
FDA issued an approval letter for RINGER'S IN PLASTIC CONTAINER on 2026-03-27. The source metadata identifies NDA 018251 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
RINGER'S IN PLASTIC CONTAINER — FDA Approval Letter (NDA 018251)
Issued to OTSUKA ICU MEDCL. Application is approved as submitted.
Issued
March 27, 2026Application
NDA 505b1 • 018251
Product
RINGER'S IN PLASTIC CONTAINER
Company
OTSUKA ICU MEDCL
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for RINGER'S IN PLASTIC CONTAINER?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 018251.
- 3Submission: supplement.
- 4Sponsor: OTSUKA ICU MEDCL.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the RINGER'S IN PLASTIC CONTAINER approval letter
Is RINGER'S IN PLASTIC CONTAINER FDA approved?
This letter documents an FDA approval action: FDA approved NDA 018251 for RINGER'S IN PLASTIC CONTAINER, sponsored by OTSUKA ICU MEDCL, on March 27, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 018251?
NDA 018251 is the application under which FDA issued this approval letter for RINGER'S IN PLASTIC CONTAINER to OTSUKA ICU MEDCL. The letter is dated March 27, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.